The size of the global computational biology market was estimated to be USD 5.85 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 13.18% to reach approximately USD 20.18 billion by 2032.
.jpg "The Global Computational Biology Market 2022-2032 (USD Billion)")
Computational biology is concerned with the use of computers for biological problems, most prominently problems in evolutionary and molecular biology. This area is also referred to as bioinformatics and these two terms are often used interchangeably. The usage of computational biology has escalated for gene sequencing and expansion, protein transcription, structural and functional epigenomic, genomics and metagenomics for the analysis of protein-protein interactions, and 3-D protein structure analysis.
Regionally, North America accounted for the largest market share of the global computational biology market attributable to industry-academia collaborations. Leading players of the global computational biology market include Computing Group Inc., Simulation Plus Inc., Compugen Ltd., Genedata AG, Insilico Biotechnology AG, Certara, Accelrys, Entelos, Rhenovia Pharma SAS, Nimbus Discovery LLC among others.
Computational Biology Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2032 |
| Study Period | 2018-2032 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2032 | USD 20.18 billion |
| Growth Rate | CAGR of 13.18% during 2022-2032 |
| Segment Covered | Application,Services, End-use, Regions |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Key Players Profiled | Computing Group Inc., Simulation Plus Inc., Compugen Ltd., Genedata AG, Insilico Biotechnology AG, Certara, Accelrys, Entelos, Rhenovia Pharma SAS, Nimbus Discovery LLC among others. |
Key segments of the global computational biology market
Application Overview (USD Billion)
- Cellular & Biological Simulation
- Drug Discovery & Disease Modelling
- Preclinical Drug Development
- Clinical Trials
- Human Body Simulation Software
Services Overview (USD Billion)
- In-house
- Contract
End-use Overview (USD Billion)
- Academics
- Industry
- Commercial
Regional Overview (USD Billion)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- GCC
- South Africa
Frequently Asked Questions (FAQ) :
The computational biology market was valued at 20.18 billion 2032
The major contenders in the global market are computational biology market include Computing Group Inc., Simulation Plus Inc., Compugen Ltd., Genedata AG, Insilico Biotechnology AG, Certara, Accelrys, Entelos, Rhenovia Pharma SAS, Nimbus Discovery LLC among others.
The Applications of the computational biology market Cellular and Biological Simulation, Drug Discovery and Disease Modeling, Pre-Clinical Drug Development, Clinical Trials, Human Body Simulation Software.
The term ‘computational biologist’ can encompass several roles, including data analyst, data curator, database developer, statistician, mathematical modeler, bioinformatician, software developer, ontologist and many more. Computers are now essential components of modern biological research, and scientists are being asked to adopt new skills in computational biology and master new terminology. Key to good computational biology is the selection and use of appropriate software. Software tools are often implementations of a particular algorithm that may be well-suited for particular types of data; for example, in de novo assembly, an Overlap-Layout-Consensus assembler is optimized for longer sequence reads, whereas de Bruijn graphs were designed with short reads in mind. Choosing software employing the most appropriate algorithm saves a lot of time.
Based on the application drug discovery is anticipated to be the fastest growing segment over the forecast period, as it helps enabling personalized medicine, predict drug effects in patients, the finding of new uses for existing drugs and improvement of the success rate of new drugs in the clinic. Based on the services that global computational biology industry is bifurcated into in-house and contract. Compared to the in-house services, contract services offers higher cost-effectiveness, just-in-time delivery with a single point of contact and offers access to wide range of industry software led to its higher adoption. On the basis of end-user, the global computational biology market is segmented into industry, commercial and academics. The segment with highest global computational biology market share is accredited to commercial. It is ascribed to growth of drug designing, personalized medicine and disease modelling, increasing number of clinical studies in pharmacokinetics and pharmacogenomics, and increase in bioinformatics research.
North America accounted for the largest share of the global computational biology market in 2020. Moreover, Asia is likely to show lucrative growth during the forecast period. North America leads the global computational biology market share with increasing initiatives and investments for R&D of novel drugs, drug discovery, technological advancements and disease modelling in biological computations. In addition to that, the US government channeled billions for the progress of synthetic biology and computational biology. The global computational biology market of Canada is anticipated to have significant growth over the forecast period, primarily due the Canadian government developing interest to advance the computational biology.